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Abstract
Background: 1974–2005 studies across Sierra Leone showed onchocerciasis endemicity in 12 of 14 health districts (HDs) and
baseline studies 2005–2008 showed lymphatic filariasis (LF) endemicity in all 14 HDs. Three integrated annual mass drug
administration (MDA) were conducted in the 12 co-endemic districts 2008–2010 with good geographic, programme and
drug coverage. Midterm assessment was conducted 2011 to determine impact of these MDAs on LF in these districts.
Methodology/Principal Findings: The mf prevalence and intensity in the 12 districts were determined using the thick blood
film method and results compared with baseline data from 2007–2008. Overall mf prevalence fell from 2.6% (95% CI: 2.3%–
3.0%) to 0.3% (95% CI: 0.19%–0.47%), a decrease of 88.5% (p= 0.000); prevalence was 0.0% (100.0% decrease) in four
districts: Bo, Moyamba, Kenema and Kono (p = 0.001, 0.025, 0.085 and 0.000 respectively); and seven districts had reductions
in mf prevalence of between 70.0% and 95.0% (p = 0.000, 0.060, 0.001, 0.014, 0.000, 0.000 and 0.002 for Bombali, Bonthe,
Kailahun, Kambia, Koinadugu, Port Loko and Tonkolili districts respectively). Pujehun had baseline mf prevalence of 0.0%,
which was maintained. Only Bombali still had an mf prevalence$1.0% (1.58%, 95% CI: 0.80%–3.09%)), and this is the district
that had the highest baseline mf prevalence: 6.9% (95% CI: 5.3%–8.8%). Overall arithmetic mean mf density after three
MDAs was 17.59 mf/ml (95% CI: 15.64 mf/ml–19.55 mf/ml) among mf positive individuals (65.4% decrease from baseline of
50.9 mf/ml (95% CI: 40.25 mf/ml–61.62 mf/ml; p = 0.001) and 0.05 mf/ml (95% CI: 0.03 mf/ml–0.08 mf/ml) for the entire
population examined (96.2% decrease from baseline of 1.32 mf/ml (95% CI: 1.00 mf/ml–1.65 mf/ml; p = 0.000)).
Conclusions/Significance: The results show that mf prevalence decreased to ,1.0% in all but one of the 12 districts after
three MDAs. Overall mf density reduced by 65.0% among mf-positive individuals, and 95.8% for the entire population.
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Introduction
Lymphatic filariasis (LF) and onchocerciasis are two of the
major neglected tropical diseases (NTDs), presently targeted for
elimination using the World Health Organization (WHO)
recommended strategy of preventive chemotherapy and transmis-
sion control (PCT) [1,2,3]. LF is a disease caused by the lymphatic
filarial roundworms Wuchereria bancrofti, Brugia malayi and Brugia
timori, and transmitted by mosquitos. It is highly endemic in the
tropics and subtropics (Africa, Asia, South Pacific and some parts
of South America). The elimination strategy is through annual
mass drug administration (MDA) with albendazole and ivermec-
tin/diethylcarbamazine [1,2]. LF elimination is implemented
through the Global Programme to Eliminate Lymphatic Filariasis
(GPELF) which has expanded MDA coverage from three million
people treated in 12 countries in 2000, to more than 450 million in
53 countries in 2010 [4,5]. During that period, the disease was
eliminated in China and Korea. Nine countries no longer require
MDA because of a natural decline in transmission intensity in
areas of low disease endemicity. Globally, a total of 73 countries
(including the recently independent Republic of South Sudan) are
presently endemic for LF. Onchocerciasis, caused by Onchocerca
volvulus, is transmitted by blackflies belonging to the Simulium
damnosum complex. It is mainly endemic in Africa, Yemen and the
Americas [6]. Control of the disease in Africa is through the
African Programme for Onchocerciasis Control (APOC) using the
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annual community-directed treatment with ivermectin (CDTI)
strategy [7]. In 2008 alone, 56.7 million people received treatment
in 19 endemic African countries [7].
In Sierra Leone, both diseases are widely distributed across the
country and co-endemic in 12 of the 14 health districts. The early
distribution and clinical manifestations of both diseases in Sierra
Leone were described in previous publications [8,9,10,11,12].
When Sierra Leone was included as part of the Onchocerciasis
Control Programme (OCP) of WHO in 1989, treatment strategy
for onchocerciasis control included aerial larviciding using
helicopters and aircrafts targeting the breeding sites of the
blackflies and ivermectin treatment as Merck & Co. Inc. had
started donation of Mectizan (ivermectin) in 1987. National
Onchocerciasis Control Programme (NOCP) records show that by
1994 annual biting rates of the savannah blackfly population
dropped from the 1988 pre-treatment level of 60 bites/person/day
to 1 bite/person/day and the community microfilaria load
decreased by over 90%. However, by 1996 onchocerciasis control
activities were stopped in all areas of the country when the civil
conflict that started 1991 engulfed the entire country. The civil
conflict ended in 2002, the same year that OCP was closed.
NOCP activities recommenced in 2003 under the Special
Intervention Zones (SIZ) established by APOC for some ex-
OCP countries, including Sierra Leone. Surveys on onchocerciasis
conducted in Sierra Leone after 2002 (unpublished NOCP data)
showed that vector biting rates and community microfilaria load
had reverted to pre-treatment levels in many communities. Since
2003 annual MDAs have been conducted for onchocerciasis
control using the CDTI strategy with technical and financial
support from APOC. The CDTI strategy, which promotes
community participation as the key aspect of ivermectin distribu-
tion to improve access to ivermectin and ensure community
ownership of the process, was adopted by APOC in the mid-1990s
after a multi-country study. At first the local health workers and
NGDO representatives introduce CDTI to the community in a
participatory manner. Through a series of community meetings
they explain the roles and responsibilities of communities in the
CDTI process. The communities themselves then direct the
planning and implementation of the interventions. The commu-
nity collectively selects the community drug distributors (CDDs)
and then plan the distribution process by deciding the method
used (house to house or central location), the place where the
distribution is conducted if fixed location is accepted, when the
distribution is conducted, by whom activities will be implemented,
how all activities will be monitored, and the support, if any, that
CDDs will receive (financial or otherwise) from the community.
With CDTI communities manage ivermectin by collecting their
supply from a central point agreed upon with the health services
and storing it within the community until the distribution period.
The health workers and NGDO representatives train, supervise
and monitor the CDDs while the community directs the process. It
has been observed that when the community takes charge of
onchocerciasis control MDAs can be sustained for up to 20 years.
Furthermore, programme costs are reduced significantly because
the community plays the leading role in all aspects of programme
implementation [13,14]. Apart from training of communities to
assume leadership of the CDTI process, NGDOs have also made
significant contribution to the CDTI process through operational
research, provision of resources to complement national pro-
grammes by supporting health staff in remote communities, and
provision of technical and financial support. An NDGO Coalition
was created in 1991 for onchocerciasis control that meets regularly
to coordinate collaboration at international and national levels
[15]. Annual MDAs using the CDTI strategy has significantly
reduced parasite prevalence and intensity in many communities of
Sierra Leone since control operations resumed in 2003 [16].
Reports from health facilities had always indicated high endemic-
ity of LF in all districts. Pre-baseline prevalence of LF was very
high in south-eastern Sierra Leone. Blacklock (1922) examined
240 men in Mabang village and found 20% to be microfilaraemic,
with prevalence of elephantiasis and hydrocoele of 4.6% and
3.8%, respectively [17]. Surveys in the early 1990s showed an
average mf prevalence of 34.8% in three villages in the Moyamba
district [18]. Similarly high prevalence rates were recorded in
neighboring Liberia prior to the 1980s [19,20]. In 2007–2008, the
pre-treatment mf prevalence for the 12 districts outside the
Western Area ranged from 0–6.9%, although prevalence was
below 3% in the south-eastern districts [21] with Moyamba district
showing pre-treatment mf prevalence of 1% (95%CI 0.4%–2.3%)
[21]. This significant reduction of mf prevalence from earlier high
levels prior to the start of the LF MDAs coincides with the
commencement of mass administration of ivermectin for oncho-
cerciasis control in the 1980s [16]. After national mapping of LF in
2005 and baseline data collection on microfilaria (mf) prevalence
and density in 2007–2008 [21], CDTI was expanded to include
albendazole distribution to control LF in six co-endemic districts in
2007 [16]. With support from the United States Agency for
International Development (USAID) NTD Control Program,
managed at the time by RTI International, the NOCP was
transformed into the National Neglected Tropical Diseases
Control Programme (NTDCP) in 2008 to upscale treatment for
LF from 6 districts to all 14 endemic districts and integrate other
NTDs such as schistosomiasis and soil transmitted helminthiasis
into the control effort [16]. After the civil war in Sierra Leone,
during which almost all health programmes had stopped, the
Ministry of Health and Sanitation (MOHS) had decided to put the
control of all NTDs under the existing onchocerciasis control
programme with 1(one) programme manager responsible for all
NTDs and working in close collaboration with strong district
health management teams (DHMTs). It was decided that running
vertical programmes for NTDs will be inefficient given the post
war situation and the limited number of health workers and so the
national coordination for NTDs had to work in close collaboration
with the DHMTs and the existing district health structure.
Author Summary
Onchocerciasis studies across Sierra Leone between 1974
and 2005 showed that 12 of the 14 health districts (HDs)
are endemic for onchocerciasis. Baseline lymphatic filariasis
(LF) studies 2005–2008 showed that all 14 HDs of Sierra
Leone are LF endemic. Three annual rounds of integrated
mass drug administration (MDA) with ivermectin and
albendazole 2008–2010 were conducted in the 12 HDs
that are co-endemic for onchocerciasis and LF with good
geographic, epidemiological drug (or programme) and
drug coverage. A midterm evaluation study of mf
prevalence and density was conducted in the 12 HDs in
2011. The hypothesis proposed for this study is that areas
previously exposed to ivermectin treatment for onchocer-
ciasis control may require less rounds of annual MDA to
eliminate LF (i.e. reduce microfilaremia (mf) prevalence to
,1%). Results of the midterm evaluation study showed
very significant and rapid reduction of mf prevalence and
density with 11 out of the 12 districts having mf
prevalence ,1%. Relatively low LF baseline prevalence
and effective integrated MDA for onchocerciasis and LF
have led to rapid reduction in LF prevalence.
Impact of 3 MDAs on LF in Sierra Leone
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Annual MDA with ivermectin and albendazole has been
implemented since then. By early 2011, all 12 rural health
districts (except Urban Western Area and Rural Western Area)
had received at least three rounds of MDA. LF antigenemia
prevalence (ICT) in 2005 was 11.7% (95% CI: 5.8%–22.2%) and
7.3% (95% CI: 3.1%–15.9%) for Urban Western Area and Rural
Western Area respectively and baseline microfilaremia prevalence
in 2008 was 0% (95% CI: 0%–0.7%) and 1.2% (95% CI: 0.6%–
2.6%) for Urban Western Area and Rural Western Area
respectively. The study presented in this manuscript is the
midterm evaluation of the LF programme in Sierra Leone as part
of the national NTD Control Programme and was conducted
following guidelines provided by WHO, which recommends
midterm programme review before the 4th round of MDA. The
2 LF-only districts were not included in this study because effective
MDA in these 2 districts started in 2010, while effective MDA in
the other districts started in 2007/2008. These 2 districts have
been treated through MDAs since 2010 but post-MDA microfil-
aremia studies have not yet been done. According to WHO
guidelines [22], a mid-term survey was conducted in July/August
2011 in sentinel and spot check sites in the 12 rural health districts.
The hypothesis of the study is that areas previously exposed to
ivermectin treatment for onchocerciasis control may require fewer
rounds of MDA to interrupt transmission of LF. Study objectives
are to assess midterm progress towards LF elimination by
measuring the microfilaremia prevalence for LF in districts that
had conducted 3 good round of MDA and identify any
implementation units (districts) that may require additional effort
to reach the target of LF elimination. In this paper we describe the
impact of three rounds of MDA on LF prevalence and mf density
in areas of low LF endemicity which may be related to previous
treatment with ivermectin for onchocerciasis control.
Methods
Ethics Statement
This study was conducted by the National NTDCP of the
MOHS, Sierra Leone as part of the routine monitoring and
evaluation activities of the national control programme. Ethical
approval for the study was obtained from the MOHS Research
and Ethics Committee. Informed oral consent was obtained from
each participant before samples were collected. Parents and
guardians provided informed consent for child participants to
participate in the study before samples were collected. The
acceptance of all participants/parents and guardians (for children)
was recorded on a form by the team leader, as literacy rates are
low in the country. All participants aged 5 years and above in each
site were eligible for inclusion without discrimination on gender,
social status, religion or ethnicity. Participants’ identities were
protected by collecting, recording and analyzing data such that
participants remained anonymous.
Mass Drug Administration
Annual MDA with ivermectin and albendazole was piloted in
2007 in six rural districts located in border areas with neighboring
Guinea and Liberia: Bombali, Kailahun, Kambia, Koinadugu,
Kono, and Pujehun. This was scaled up to cover 12 rural districts
in 2008 with six additional districts added to the previous six: Bo,
Bonthe, Kenema, Moyamba, Port Loko and Tonkolili. Geo-
graphic coverage for the endemic districts targeted reached 100%
in 2010 when MDA was scaled up to cover the remaining two
health districts: Urban Western area and Rural Western area [23].
Within rural communities ivermectin and albendazole were
distributed by CDDs who are literate members of the respective
communities selected by their communities and trained by health
workers. CDDs are trained by district health workers to conduct
pre-MDA census, house-to-house visits in the village, treat all
eligible members of the community by observing them while they
take the doses, conduct follow up visits to treat absentees and
complete the relevant reporting tools used at community level. 1
CDD is trained to cover approximately 100 people and for Sierra
Leone where the average population per community is about 200,
each community has on average 2 CDDs. In urban areas the
programme tried but could not succeed in getting community
volunteers (CDDs) to distribute the ivermectin and albendazole
without getting any financial payment as in rural areas and so
students in medical and nursing institutions were trained and paid
to conduct MDAs. District health workers conduct trainings for
MDA and provide supervision during MDAs. NTDCP staff and
members of the DHMTs also supported training and supervision
for MDAs. MDA is conducted once a year between September
and December, which is the post-harvest period that communities
have accepted for MDAs.
Before each MDA, CDDs conduct a pre-MDA census. Details
on all community members are recorded in the community
registers and updated each year prior to subsequent MDA. MDA
details are also captured in the registers. After each MDA, details
are summarized in the reporting forms by drug distributors and
submitted to the supervising health workers. The supervising
health workers prepare summary reports for all villages/urban
areas targeted and submit the reporting forms to the DHMTs.
Each DHMT then submits the district MDA report to the
NTDCP, which collates MDA results from all districts. It should
be noted that all activities were co-implemented for both
onchocerciasis and LF control starting from trainings of district
health workers and CDDs, community sensitization and mobili-
zation, advocacy and mass distribution of ivermectin and
albendazole. The NTD control programme is also strongly
integrated in the national and district health system and has
benefitted from a well-structured health system at district level that
has a focal person responsible for NTD control within each
district, which ensures high treatment and geographic coverage.
MDA in the 6 districts that piloted MDA for LF in 2007 took
place in rural areas (villages) only as the main aim of this pilot
MDA was to see how the CDDs and the district health workers
can manage integrated MDA for onchocerciasis and LF (i.e.
distribution of both ivermectin and albendazole). The onchocer-
ciasis control programme is not implemented in urban areas with
large populations or populations greater than 2000 people.
Therefore, the integrated MDA in 2007 was done only in areas
previously treated for onchocerciasis. As the 6 districts that piloted
MDA for LF in 2007 did not cover the urban areas (i.e. district
headquarter towns and other large towns with population .2000
people) with relatively poor treatment coverage (well below 65%),
the 2007 MDA results were considered inadequate. It was only in
2008 that urban areas of the 12 districts were treated using health
workers as distributors. 2008 is therefore considered year 1 when
MDA results were ‘‘adequate’’ as treatment coverage was above
65% and geographic coverage was 100%. Please see tables 1 and 2
for districts that conducted pilot MDA in 2007.
Survey Site Selection
34 Villages were randomly selected by AFRO in Brazzaville
using the available database for villages in Sierra Leone in 2005
with at least 2 villages selected per district depending on the
population and sent to the programme. After the mapping in
2005, villages with relatively very high antigenemia prevalence
were selected for all 14 health districts as sentinel sites for the
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baseline mf survey in 2007/2008. The number of sentinel sites
selected per district depended on the population of the district.
The then WHO guidelines recommended 1 sentinel site per
500,000 population and 1 sentinel site was selected for districts
with population less than 500,000 and 2 for districts with
population more than 500,000 [21,24].
Sampling for the midterm survey July/August 2011 was
conducted in accordance with new WHO guidelines in one
sentinel site and one spot check site per population of one million
people [22]. The 12 rural districts that had conducted at least
three rounds of MDA were involved in this study. As the
populations of the districts were small, the 12 districts were put in
six groups of two districts depending on geographical proximity
and epidemiological characteristics so that the total population for
each group was about a million [22]. In each of the six groups
(table 3), a sentinel site was selected in one district for this study,
and a spot check site was selected in the other district, in
consultation with the DHMTs. The groups included the following
pairs of districts: Bonthe (sentinel site (SS)- Moboya) and
Moyamba (spot check site (SCS)- Taninahun Kapuima); Koina-
dugu (SS-Kumala) and Bombali (SCS-Makoba Yelima); Bo (SS-
Gelehun) and Pujehun (SCS- Kundorwahun); Port Loko (SS-
Gbabai) and Kambia (SCS- Kamasasa); Kailahun (SS-Manowa)
and Kenema (SCS- Joru); Kono (SS- Tombodu) and Tonkolili
(SCS-Rosint). In the ‘‘sentinel site’’ districts data obtained in this
study were compared with baseline data, while among the ‘‘spot
check site’’ districts, the results of this survey were compared with
baseline results obtained in the original sentinel sites in these
districts.
The spot check sites were selected in consultation with DHMTs
because according to WHO guidelines of 2011 spot check sites are
to be selected according to the local knowledge where LF is most
likely to be found as the objective of LF control is elimination [22].
By consulting with DHMTs and selecting areas where LF
prevalence could be high the possibility of selecting spot check
sites that will have zero prevalence while there were areas with
high prevalence within the same districts might have been avoided
[22].
Recent WHO guidelines [22] recommend study of a minimum
of 300 participants per sentinel/spot check site but villages in
Sierra Leone generally have small populations (average of 250)
and so in most cases all those 5 years and above that volunteered
in the sentinel/spot check villages were simply selected while
others in neighboring villages were randomly selected to have a
number greater than 300 participants. WHO recommends
convenience sampling for any group selected for LF survey
because they are seen to be at high risk [22].
Sampling and Diagnosis
The survey teams met with community leaders upon arrival in
communities and explained the nature of their work, after which,
meetings were held with the general community to explain the
study and its significance and respond to questions from
community members before the study was conducted. Some
300–500 participants of 5 years of age or above were recruited per
site according to WHO guidelines [22]. In sites with less than 300
participants, more participants were recruited in neighboring
villages. To ensure standardization of activities and data, two-day
practical training was conducted for all technicians before the
study started. Fingertip blood was collected between 10 pm and 2
am. A 60 ml blood sample was collected from each participant,
smeared gently and uniformly in a circular shape and allowed to
air dry at room temperature for 12–24 hours. The next day, the
dried smear was dehaemoglobinized through flooding with
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distilled water for 3–5 minutes, air dried again, fixed with
methanol for 30–60 seconds, stained with GIEMSA for 10 min-
utes, and examined for mf under a light microscope by
experienced examiners. The640 objective was used to first locate
the mf by moving patiently from left to right or right to left starting
at the extreme top end of the thick blood film and moving through
all available fields; then moving slightly downwards and repeating
the same process of moving from left to right or right to left until
all areas of the thick blood film are covered. When mf is located
the filarial species was identified using 6100 objective [22]. A
minimum of 50 microscopic fields were examined before a
specimen was considered negative. The research team included
laboratory technicians from the national reference laboratory and
the University of Sierra Leone who have adequate experience in
diagnostic detection of filarial parasites. The team leader was also
supported in 2007 by WHO and the NTD Support Center in
Ghana to receive further training on detection of filarial parasites
at the Noguchi Memorial Institute for Medical Research in Accra,
Ghana. Positive findings of mf were recorded and individual mf
density of infection was calculated and expressed as the number of
mf per ml of blood (mf/ml). A total of 6,023 ‘‘midnight’’ blood
samples were collected and examined for mf as shown in table 1,
male 3,170 (52.6%) and female 2,853 (47.4%). The mean age (6
standard deviation) of the subjects examined was 28.91618.92
years (males: 27.65618.77, females: 30.32618.92). For quality
control, all positive slides and 10% of the negative slides were
preserved and examined by a researcher, who was invited during
the design of the study to help in designing the study and to
conduct the quality control because he has been involved in the
study and detection of filarial parasites since 1995–1996 [18].
There were only 18 positive slides and these were submitted for
quality control together with 600 randomly selected negative
slides. Results of the quality control showed that all 18 positive
slides were true positives while the negative slides were all true
negatives. The coordinates of each sample site were recorded using
hand-held units of global positioning system (site coordinates
available upon request).
Statistical Analysis
Results were entered into MS Excel and analyzed in SPSS
(IBM, Version 19). Prevalence and density of mf were calculated
for all 12 districts and compared with the baseline data. The 95%
confidence intervals (CIs) for prevalence were calculated using the
Wilson score method without continuity correction [25]. The
arithmetic mean mf density of infection with 95% CI was
calculated using the total population examined and the positive
samples only [21,24]. The Chi-squared test was used to compare
the differences in prevalence and the Kruskal-Wallis test was used
to compare the differences in mf density. Treatment coverage was
calculated according to the WHO guidelines [22]. Epidemiolog-
ical drug coverage (EDC), otherwise known as Programme
coverage, is the treatment coverage reported using total
population of IU as denominator and is calculated as the number
of people who were reported to have ingested the medicines for
LF divided by total population in IU multiplied by 100. The
epidemiological drug coverage calculated using the total popu-
lation of the IU is a reflection of what proportion of the at-risk
population is being covered by MDA. Drug coverage (DC) is the
treatment coverage reported using individuals targeted or eligible
for treatment in the IU as denominator and is calculated as the
number of people who were reported to have ingested the
medicines for LF divided by all individuals targeted or eligible for
treatment in the IU multiplied by 100. The drug coverage in the
targeted or eligible population is considered the best measure of
how well MDAs are implemented. An adequate level of EDC is
estimated to be 80% and the DC should be close to 100%. These
indicators enable IU authorities to assess the status of the
elimination programme. WHO recommends that programme
managers use the reported coverage to identify areas with low
coverage, investigate the causes and find solutions that will
improve programme implementation as the programme contin-
ues [22]. The total population for rural areas used as
denominator for analyzing MDA results was the total number
of people registered during the pre-MDA census, while the total
population used in urban/non-rural areas was the projected
figure according to the 2004 national census [26], with an annual
growth rate of 2.5%. Spatial analysis of the LF mf prevalence was
conducted using the kriging method in the Geostatistical Analyst
Extension of ArcGIS version 10 (ESRI, Redlands, USA).
Spatially smoothed contour maps of the interpolated prevalence
of mf at baseline and after three MDAs were produced as
described previously [21,27].
Results
Mass Drug Administration Results 2008–2010
A total of 14,253 villages and urban areas were treated for LF
each year during the 3 years in the 12 districts. As all the villages
and urban areas were treated in each of the 12 districts, this
represents 100% geographic coverage for endemic villages and
urban areas in all 12 districts during each of these 3 rounds of
MDA, as shown in table 2. Over 4 million people were targeted for
treatment each year during the 3 years. Overall EDC was 70.1%,
74.1% and 75.2% in 2008, 2009 and 2010 respectively at the
national level, and was $65.0% in each district in each round,
except in Bonthe, where it was 59.5% in 2008. EDC also
improved between 2008 and 2010. Five districts had ,70.0% in
2008 (Bo: 66.3%, Bonthe: 59.5%, Kono: 69.0%, Port Loko:
66.6% and Tonkolili: 68.6%); while in 2009 and 2010, all districts
had .70.0% EDC, as shown in table 2. The overall DC was
82.5%, 87.1% and 88.5% in 2008, 2009 and 2010, respectively.
The DC is a measure of how well MDA was conducted and is
considered adequate when $80.0% [22]. DC by district in each
round was $80.0%, except in Bo, Bonthe and Port Loko, which
had 78.0%, 70.0% and 78.3% respectively in 2008, as shown in
table 2.
Table 3. Survey site selection.
Groups of districts Districts Sentinel sites Spot check sites
1 Bonthe Moboya -
Moyamba - Taninahun Kapuima
2 Koinadugu Kumala -
Bombali - Makoba Yelima
3 Bo Gelehun -
Pujehun - Kundorwahun
4 Port Loko Gbabai -
Kambia - Kamasasa
5 Kailahun Manowa -
Kenema - Joru
6 Kono Tombodu -
Tonkolili - Rosint
doi:10.1371/journal.pntd.0002273.t003
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Microfilaraemia Prevalence
Five districts (Bo, Kenema, Kono, Moyamba and Pujehun) had
0.0% mf prevalence. One district (Pujehun) had baseline mf
prevalence of 0.0%, which was maintained. Another six districts
had mf prevalence between 0.0 and 1.0%: Bonthe (0.20%; 95%
CI: 0.04%–1.13%), Kailahun (0.20%; 95% CI: 04%–1.13%),
Kambia (0.40%; 95% CI: 0.11%–1.45%), Koinadugu (0.80%;
95% CI: 0.31%–2.05%), Port Loko (0.20%; 95% CI: 0.04%–
1.13%) and Tonkolili (0.19%; 95% CI: 0.03%–1.08%). Only one
district had mf prevalence of over 1%: Bombali (1.58%; 95% CI:
0.80%–3.09%). Overall mf prevalence among males was 0.35%
(95% CI: 0.19%–0.62%), and among females 0.25% (95% CI:
0.12%–0.51%). Prevalence by age group, 5–14 years (N= 1947),
15–20 years (N= 858), 21–30 years (N=858), 31–40 years
(N= 849) and 41–50 years (N=640), was 0.21% (95% CI:
0.08%–0.53%), 0.12% (95% CI: 0.02%–0.66%), 0.58% (95%
CI: 0.25%–1.36%), 0.59% (95% CI: 0.25%–1.37%) and 0.47%
(95% CI: 0.16%–1.37%) respectively, while prevalence in the age
group .50 years (N= 871) was 0.0%. In total, 18 persons (0.30%,
95% CI: 0.19–0.47%) had a positive blood smear, and there was
Figure 1. Survey sites and spatially smoothed contour maps of predicted LF mf prevalence in Sierra Leone. A. Predicted mf prevalence
at baseline; B. Predicted mf prevalence after three rounds of MDA. The same legend scale was used for the contour map of both A and B for easy
comparison. Triangles and labels show the survey locations and the observed mf prevalence in each location.
doi:10.1371/journal.pntd.0002273.g001
Figure 2. Reduction of MF prevalence after 3 annual MDAs for
LF in Sierra Leone 2008–2010.
doi:10.1371/journal.pntd.0002273.g002
Figure 3. Reduction of entire-population mf density after 3
annual LF MDAs in Sierra Leone 2008–2010.
doi:10.1371/journal.pntd.0002273.g003
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no significant difference in mf prevalence in males as compared to
females (p = 0.47). There were also no significant differences in
prevalence among age groups.
Compared with the baseline, overall mf prevalence decreased
by 88.5% (p= 0.000), from 2.6% (95% CI: 2.3%–3.0%) to 0.30%
(95% CI: 0.19%–0.47%), after 3 rounds of MDA. As shown in
table 1, among the 11 districts with baseline mf prevalence $1%,
seven districts showed mf prevalence reduction of over 90% after
three rounds of MDA, three districts by over 80%, and only one
district by below 80%. Spatial prediction suggested a sweeping
reduction in mf prevalence from the baseline level after three
MDAs across the country. There was an 89.4% decrease
(p = 0.000) in mf prevalence among males: 3.3% (95% CI:
2.8%–3.9%) to 0.35% (95% CI: 0.19%–0.62%); and an 87.5%
decrease (p = 0.000) in mf prevalence among females: 2.0% (95%
CI: 1.6%–2.4%) to 0.25% (95% CI: 0.12%–0.51%). There was
0.21% (95% CI: 0.08%–0.53%) prevalence among the age group
5–14 years, but this could not be compared, as the baseline study
did not include participants ,15 years. Decreases in mf
prevalence among the age groups 15–20, 21–30, 31–40, 41–50
and .50 years ranged between 77.3% and 100.0% (p= 0.000,
0.000, 0.000, 0.000 and 0.000 respectively). Figure 1 shows
predicted mf prevalence at baseline (A) and predicted mf
prevalence after three rounds of MDA (B). Figure 2 shows the
overall decrease in mf prevalence and the decrease for each
district. A statistical comparison between the 6 districts that piloted
MDA for LF in 2007 and the other 6 showed no statistical
difference between the decreases in microfilaremia prevalence of
the 2 groups of districts. 3 out of the 4 districts that had 100%
decreases in mf prevalence had conducted only 3 MDAs.
Microfilaraemia Density
The overall arithmetic mean mf density was 0.05 mf/ml (95%
CI: 0.03 mf/ml–0.08 mf/ml) in the total participants examined
and 17.59 mf/ml (95% CI: 15.64 mf/ml–19.55 mf/ml) among
mf-positive individuals. The mean mf density by district was well
below 1 mf/ml for the population examined and below 21 mf/ml
among those who were mf positive. There was no significant
difference in mf density in males versus females (p.0.05). There
was also no significant difference in mf density among age groups
in the total population examined (p.0.05). Overall mean mf
density among mf positive individuals decreased by 65.4%
(p= 0.001), from 50.9 mf/ml (95% CI: 40.25 mf/ml–61.62 mf/
ml) at baseline to 17.59 mf/ml (95% CI: 15.64 mf/ml–19.55 mf/
ml); and in the total population examined, there was a 96.2%
decrease (p = 0.000), from 1.32 mf/ml (95% CI: 1.00 mf/ml–
1.65 mf/ml) at baseline to 0.05 mf/ml (95% CI: 0.03 mf/ml–
0.08 mf/ml). In Bo, Kenema, Kono and Moyamba, there was
100.0% decrease in mf density among both mf positive
participants and the entire population. Six districts, Bonthe,
Kailahun, Kambia, Koinadugu, Port Loko and Tonkolili, had a
.90.0% decrease in mf density for the entire population
(p = 0.059, 0.001, 0.014, 0.000, 0.000 and 0.002 respectively),
and a .36.0% decrease in mf density among positive participants
(p = 0.295, 0.472, 0.311, 0.454, 0.219 and 0.442 respectively).
Bombali had the lowest decreases in mf density, 86.3% for the
entire population (p = 0.000) and 40.6% among positive individ-
uals (p = 0.068). Table 1 shows the reduction of mf density in the
12 districts after 3 MDAs. There was a 96.7% decrease in mf
density among all males (p = 0.000) and a 67.0% decrease in mf
density among males that are mf positive (p = 0.013); and there
was a 95.4% decrease in mf density among all females (p = 0.000)
and a 62.8% decrease in mf density among females that are mf
positive (p = 0.023). The age groups 15–20, 21–30, 31–40 and 41–
50 years had .90.0% decrease in mf density for the entire
population (p= 0.000, 0.000, 0.000 and 0.000 respectively) and
.60.0% decrease in mf density among mf positive individuals
(p = 0.341, 0.042, 0.059 and 0.159 respectively). The age group
.50 years had a 100.0% decrease in mf density for the entire
population and among mf positive individuals. For details of mf
prevalence and density at baseline and after 3 MDAs, reductions
in mf prevalence and density after 3 MDAs and p values for the
reductions in prevalence and density please see table 1. Figures 3
and 4 show overall and district decreases in mf density for the
entire population and for those who were mf positive respectively.
Discussion
LF is widely endemic across Sierra Leone, transmitted by
Anopheles mosquitoes. All 14 health districts qualified for MDA
intervention in accordance with WHO guidelines because they
had baseline LF prevalence by ICT cards $1.0% [21,24].
Although MDA was piloted in rural areas of 6 health districts in
2007, the 2007 MDA results were relatively poor and considered
‘‘inadequate’’ and so 2008 is considered year 1 for LF MDA when
treatment and geographic coverage was $65% and 100%
respectively. The results from the 12 rural districts showed that
over the three years (2008–2010), geographic coverage was 100%
in all 12 districts, EDC was $65.0% in all districts except for
Bonthe in 2008 (59.5%), and DC was $80.0% in all districts
except for Bo (78.0%), Bonthe (70.0%) and Port Loko (78.3%) in
2008. The treatment coverage was verified through independent
monitoring activities, as described previously [23]. The current
assessment showed that the average mf prevalence in the country
was only 0.30% and the average population mf density was only
0.05 mf/ml after three rounds of MDA, with no microfilaria
detected in six of the 12 districts, including all the districts in the
Southern Province and only one district showing mf prevalence of
.1% (Bombali, 1.58%). This represents an overall reduction of
87.5% in mf prevalence and 95.5% in population mf density. The
zero mf prevalence recorded for Pujehun district at baseline may
have been as a result of the randomness of the selection of the
sentinel sites. Consequently, a spot check site was selected in
Pujehun for the midterm study in consultation with the DHMT of
Pujehun district based on results of reported hydroceles and
Figure 4. Reduction of positive-only mf density after 3 annual
LF MDAs in Sierra Leone 2008–2010.
doi:10.1371/journal.pntd.0002273.g004
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lymphedema, which increased the chances of finding mf positive
cases. Since the mf prevalence is again zero it is recommended that
another spot check site be selected for the next survey in the
district (the pre-transmission assessment survey). The use of pre-
MDA census data as denominator in rural settings versus use of
projected census population as denominator in urban or non-rural
settings for the calculation of MDA results may have created bias
in terms of interpretation and comparability of MDA results.
However, it should be noted that the issue of what denominator to
use for MDAs in urban settings still has to be resolved by the
international NTD community as this poses a big challenge for
national control programmes. Pre-MDA census in urban settings
could be cumbersome, very expensive and results reported cannot
be easily validated. The NTDCP therefore decided to use
projected census figures as denominator in the analysis of MDA
results for non-rural or urban areas of the districts.
The number of MDA rounds needed to eliminate LF depends
on baseline infection rates, vectoral capacity, efficacy of the MDA
regimen used, and community compliance with treatment. It is
possible to eliminate LF in some implementation units (IUs) with
low baseline infection rates using less than five rounds of MDA,
while more than six MDA rounds may be needed for IUs with
relatively high baseline LF prevalence [28,29,30]. The high level
of reduction in mf prevalence and intensity after three rounds of
MDA in Sierra Leone may have been partly due to the relatively
low baseline mf level [21].
Several studies on LF conducted before the baseline studies in
2007/2008 in Sierra Leone and neighboring Liberia show mf
prevalence $20% but the LF prevalence at baseline (2007/2008)
ranged from 0%–6.9% for all districts with prevalence of the
southeastern districts that were studied previously,3% at baseline
[21]. Many studies have shown that there are 3 drugs that have
microfilaricidal effect on the lymphatic filarial roundworms and
are available for LF treatment: diethylcarbamazine (DEC),
ivermectin and albendazole. Treatment with DEC or ivermectin
alone significantly reduces blood mf levels (up to 90% mf clearance
is reported) but combination of both drugs is more effective than
using one drug. The marked filaricidal effect of these drugs makes
them suitable for annual treatment designed to control transmis-
sion immediately and in the long term to control morbidity [31].
In Burkina Faso and India it was demonstrated that 5–14 years of
ivermectin treatment (i.e. treating with ivermectin alone) reduced
mf prevalence and intensities of W. bancrofti but transmission was
not interrupted. The treatment rounds with ivermectin alone can
significantly reduce prevalence and intensity of W. bancrofti
microfilaremia, which provides an opportunity for synergy where
onchocerciasis and LF are coendemic [32,33,34]. It is reported
that there is a strong relationship between mf prevalence and
intensity in humans and mf intake and development in the
mosquito vector which means that lower intensity can lead to
reduced transmission [34,35]. The mass administration of
ivermectin for onchocerciasis control using the CDTI strategy,
which has been demonstrated to be very effective in reaching the
target communities and populations, could have been responsible
for the reduction in mf prevalence and density at baseline as
indicated in previous studies mentioned above. The reduction in
mf prevalence as a result of ivermectin treatment could have
resulted in reduced transmission among the populations of the 12
districts because mf intake and development within the vector
depends on the level of mf prevalence and density. Low mf
prevalence and density could have resulted in reduced mf intake
and development in the mosquito vector, reduced mf transmission
and therefore even further reduction of mf prevalence and density
in the populations with time.
By studying infection and infectivity prevalence in the vector
mosquitos it was demonstrated in Nigeria that 5 years of semi-
annual MDAs with ivermectin alone targeted at onchocerciasis
control reduced but did not interrupt transmission of W. bancrofti
[36,37]. Adding albendazole provided better mf clearance (up to
99%) and clearance of soil transmitted helminths in communities
treated [34,35]. Addition of albendazole to ivermectin significantly
reduced mf prevalence in mosquitos in the sentinel villages
studied, which was an entomological confirmation of the
importance of albendazole for LF control [36,37]. This observa-
tion is related to our proposed hypothesis for the study (‘‘areas
previously exposed to ivermectin treatment for onchocerciasis
control may require less rounds of annual MDA to eliminate LF’’).
Since the populations of the 12 districts had been exposed to
ivermectin treatment for onchocerciasis control, this could have
resulted in massive lowering of mf prevalence and density because
ivermectin can reduce mf prevalence by up to 90%. The mf
population was already under a selective pressure (based on the
massive use of ivermectin), and this selective pressure was
enhanced with the addition of a second drug (albendazole) to
the MDA that has been occurring for years.
The successful implementation of the LF programme benefited
from the existing onchocerciasis control programme by using
CDTI as the platform [16]. The Onchocerciasis control
programme was already well established using the CDTI strategy
which allows communities to be in charge of all programme
activities that are implemented within communities thus ensuring
good sense of ownership and good compliance within communi-
ties. Health workers had already been trained and were available
to provide technical support in additional training, supervision and
surveys. Treatment has been given between September and
December each year, as this is the period that was found to be
convenient for the communities (i.e. harvest and post-harvest
period). With integration of Onchocerciasis control and LF control
CDTI plus (CDTI+) was adopted with the same principles as
CDTI and Albendazole added to Ivermectin [16,24,35]. All the
lessons learnt from CDTI during the years of the onchocerciasis
control programme were used to improve the LF elimination
programme, such as the use of the good health infrastructure in
the districts that had focal persons for coordinating onchocerciasis
control within districts to ensure a high treatment and geographic
coverage by the national programme. These district onchocerciasis
coordinators became district NTD coordinators. After the civil
war in Sierra Leone in 2002, during which almost all health
programmes had stopped, the MOHS had decided that running
the onchocerciasis control programme as a vertical programmes
would have been inefficient given the post war situation and the
limited number of health workers and so the national coordination
had to work in close collaboration with the DHMTs and within
the existing district health structure. Furthermore, community
directed interventions were continued for control of onchocerciasis
and LF with which communities plan activities with health
workers, decide treatment periods and select volunteers who are
trained to distribute ivermectin and albendazole in their own
communities.
Three rounds of MDA with compliance $65.0% in Papua New
Guinea reduced mf prevalence from 18.6% to 1.3%, a 94.0%
reduction [38]. The authors believed that the large decrease in
prevalence occurred in part because the vector transmitting LF in
the study area was the Anopheles mosquito, which is less efficient
than Culex in the transmission of filariasis [38]. This may have also
been the case in Sierra Leone. Similar successes in reducing mf
prevalence after annual MDA rounds have been reported by many
authors. In Kenya, there were similar reductions in mf prevalence
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(from 20.9% to 0.9%, a 95.7% reduction of mf prevalence) even
when there were missed rounds of MDA [39]. Prevalence was
reduced by 93.0%, from 12.0% to 0.8%, after just 2 rounds of
MDA in Vanuatu [40]. In Northern Uganda, a reduction of mf
prevalence from 3.7% to 0.4% (a 89.2% decrease) was reported
after 3 MDAs [41]. Therefore, it is not surprising that three
effective rounds of MDA would reduce the mf prevalence to below
1% in 11 out of 12 districts in the current LF elimination
programme, given the relatively low mf prevalence at baseline.
The NTDCP in Sierra Leone has succeeded in building on an
existing and effective CDTI programme for integrated manage-
ment of onchocerciasis and LF and had the unique opportunity of
using the integrated approach of managing both onchocerciasis
and LF for LF elimination. As a result of the effectiveness of
ivermectin alone in reducing LF in endemic communities baseline
LF prevalence was relatively low. The NTDCP was able to use the
good health infrastructure in the districts that had focal persons for
coordinating NTD control within districts to ensure a high
treatment and geographic coverage. Other countries embarking
on LF elimination can learn the following lessons: in countries
where the onchocerciasis control programme already exists and is
successfully implemented, NTD control programmes can build on
the existing CDTI structure for elimination of LF; integrated
approach can be used for management of onchocerciasis and LF
in areas co-endemic for onchocerciasis and LF (all activities can be
co-implemented for the 2 diseases from training, community
sensitization and mobilization to the MDA itself); in areas where
CDTI has been implemented for many years programmes should
expect to have relatively low baseline prevalence; integration of
NTD control activities into strong existing national and district
health system can ensure good programme implementation and
improve programme sustainability especially for post MDA
surveillance. Most African countries have problems providing
adequate number of staff for public health programmes and
integrating NTD programme into the national and district health
system and co-implementation of activities for control of multiple
NTDs can improve programme effectiveness and sustainability. It
should be noted also that use of CDDs who do not get financial
payments for the services they render may not work for MDAs in
urban areas. The main difference noted in the NTDCP in Sierra
Leone is that after the civil war 1991–2002, during which almost
all health programmes had stopped, the MOHS had decided to
put the control of all NTDs under the existing onchocerciasis
control programme with 1(one) programme manager responsible
for all NTDs and working in close collaboration with strong
DHMTs. It was decided that running vertical programmes for
NTDs will be disastrous given the post war situation and the
limited number of health workers. This decision was easy to
implement because before 2005–2008 when studies were con-
ducted to map the other NTDs only the Onchocerciasis Control
Programme was existing in the country.
The use of different sites for comparison (sentinel sites in 6
districts versus spot check sites for the other 6 districts) might be a
limitation of the study considering the comparability of the impact
assessment done in the districts where the same site was used
relative to the districts where different sites were used. However,
this depends on how you look at the study. In terms of the
programme implementation it is not a limitation because recent
WHO guidelines (WHO 2011) recommend 1 sentinel site per 1
million people. Only 1 district in Sierra Leone (the Urban Western
Area, which is not in this group of 12 districts) has more than 1
million people and should have 1 sentinel site and 1 spot check site
(total of 2 sites). The rest have far less than 1 million people per
district and so have been grouped as recommended by WHO [22]
depending on geographical proximity and epidemiological char-
acteristics so that each pair has a total population of about 1
million people. Bonthe and Moyamba for example are geograph-
ically neighboring districts and have low baseline antigenemia and
microfilaremia prevalence. The pair should have 1 sentinel site
and 1 spot check site, so the sentinel site (selected and used for the
baseline microfilaremia study) was used as sentinel site for the pair
(in the case of Bonthe/Moyamba, Moboya in Bonthe was selected
as a sentinel site) and a spot check site was selected in the other
district as explained above (Taninahun Kapuima was recom-
mended by the district health management team as good spot
check site). The possible limitation for our paper is that we use the
results obtained in the spot check sites and compare with baseline
results in villages previously considered sentinel sites. Given the
overall relatively low baseline microfilaremia prevalence and the
pattern that emerges of a huge decrease noted in this mid-term
evaluation, we believe that the impact assessment done in the
districts where the same site was used relative to the districts where
different sites were used are comparable if only to assess impact of
MDA. In the case of Pujehun that had baseline mf prevalence of
zero with the possibility that due to random selection the endemic
areas (communities) might have been missed during the random
selection of the sentinel sites at baseline, we think it is prudent to
select and study another site/village that is indicated to be more
LF endemic. In the pre-6th MDA survey (pre-TAS), it will be
recommended that another spot check site be selected, which is
even more likely to be LF endemic in Pujehun to avoid risk of
overlooking villages that could possibly still be a source of LF
transmission within the district.
There is reason for optimism with the results of this survey
because some research suggests that residual infections of filariasis
disappear when prevalence is below 1.0% [42]. However, it is
prudent to consider experiences and lessons learnt from other
countries. In Tanzania, it was demonstrated that MDA using
ivermectin and albendazole reduced mf prevalence by 21.2% and
40.4% after the first and second MDA respectively, but in
subsequent MDAs, the effect leveled off and transmission, albeit
low-level, was still noted after the third MDA [43]. In Leogane,
Haiti, there was a significant reduction in mf rates after several
rounds of MDA for LF, but transmission was not interrupted [44].
Mf prevalence detected after 3 MDAs does not demonstrate a
change in filariasis transmission [38,41]. The drug combination
destroys the microfilaria over the 4–6 year it takes for the adult
worm to die a natural death [38,41,45]. Therefore, MDA has to
continue each year for 4–6 years, which is equivalent to the
lifespan of the adult worm.
In conclusion, there was significant reduction of mf prevalence
and density across the 12 rural districts in Sierra Leone after three
annual MDAs. This was coupled with good MDA compliance and
relatively low baseline endemicity. The results show that the
proposed hypothesis is highly probable and that the LF
elimination programme in Sierra Leone is on course to reach
the objective of eliminating LF by the year 2020. Eliminating
diseases such as LF has to follow models that use rigorous scientific
data as is being demonstrated in this case. The next logical steps
after the midterm evaluation include the following: continuation of
annual MDAs for another 3 years (4th, 5th and 6th MDA rounds); a
pre-transmission assessment survey (pre-TAS) before the 6th MDA
rounds; a TAS after the 6th MDA rounds if district mf prevalence
continue to be below 1%; and then 2 more TAS at intervals of 2–3
years before a request is made for certification of elimination.
Manifestations of LF such as lymphoedema and hydroceles have
to be included within the national surveillance system and
monitored closely by the NTDCP.
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